AgingResearch.NewsJoin free

InFlectis BioScience

CompanyFranceFounded 2013

RORWikidata

InFlectis BioScience develops one asset, in phase 2 (sephin1 in ALS). Mostly small molecule acting on PPP1R15A and proteostasis; based in France, founded in 2013.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1

  • sephin1

    Selective inhibitor of PPP1R15A (GADD34) holophosphatase complex, prolonging eIF2alpha phosphorylation and proteostasis

    Phase 2, Small molecule, PPP1R15A, Proteostasis, ALS, amyotrophic lateral sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Similar companies6

Intelligence